EULAR/American College of Rheumatology (ACR) risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia
An erratum to this article was published (Ann Rheum Dis, Nov 2026 ↗)
Authors' conclusion
EULAR/ACR risk stratification criteria have been developed for people with arthralgia in secondary care who are considered at risk for RA.
Study context
- Population
- Persons presenting with arthralgia considered at risk of rheumatoid arthritis (RA) (clinically suspect arthralgia and autoantibody-positive arthralgia), 10 cohorts
- Participants
- 2,293 persons10 arthralgia cohorts
- Comparison
- Clinical and serologic criteria without vs with ultrasound (US) or magnetic resonance imaging (MRI) subclinical joint inflammation variables
- Outcome
- Progression to clinically apparent inflammatory arthritis (IA)
- Follow-up
- 1 year
Methodological detailsjoint EULAR/ACR expert committee, 10 arthralgia cohorts
- Joint EULAR/ACR expert committee
- 10 arthralgia cohorts
Performance
As reported in the abstract
Discrimination for IA development
| Test or model | AUC | Sensitivity and specificity |
|---|---|---|
| Clinical + serologic | 0.80 (95% CI, 0.77-0.83) | — not stated in the abstract |
| Clinical + serologic + MRI | 0.87 (95% CI, 0.82-0.90) | >75% |
AUC
Clinical + serologic0.80 (95% CI, 0.77-0.83)
Clinical + serologic + MRI0.87 (95% CI, 0.82-0.90)
Sensitivity and specificity
Clinical + serologic— not stated in the abstract
Clinical + serologic + MRI>75%
— not stated in the abstract
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia. Ann Rheum Dis. Published 8 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →